NanoViricides Continues To Advance Broad-Spectrum Antiviral Drug NV-387 Towards Phase II Clinical Trial Of NV-387 Oral Gummies Formulation As Treatment For Current Bundibugyo Ebolavirus In DRC

뉴스 본문을 불러오고 있어요.

NanoViricides Continues To Advance Broad-Spectrum Antiviral Drug NV-387 Towards Phase II Clinical Trial Of NV-387 Oral Gummies Formulation As Treatment For Current Bundibugyo Ebolavirus In DRC | 웨이프 WAPE

NanoViricides Continues To Advance Broad-Spectrum Antiviral Drug NV-387 Towards Phase II Clinical Trial Of NV-387 Oral Gummies Formulation As Treatment For Current Bundibugyo Ebolavirus In DRC

기사 요약

관련 종목

댓글 —